Mutation frequencies in murine keratinocytes as a function of carcinogenic status

Molecular Carcinogenesis

Volumn 40, Issue 2, 2004, Pages 122-133

  Christensen, Laura A ^a   Conti, Claudio J ^a   Fischer, Susan M ^a   Vasquez, Karen M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinogenesis; Keratinocyte; Malignant progression; Mutagenesis

Indexed keywords

DNA; PSORALEN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; GENE; GENE MUTATION; KERATINOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE;

ANIMALS; BASE SEQUENCE; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; CROSS-LINKING REAGENTS; DNA DAMAGE; FICUSIN; GENE FREQUENCY; GENES, SUPPRESSOR; KERATINOCYTES; MICE; MICE, INBRED SENCAR; MOLECULAR SEQUENCE DATA; MUTATION; PAPILLOMA; PLASMIDS; REFERENCE VALUES; RNA, TRANSFER;

MURINAE; VECTORS;

EID: 2942532389     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20026     Document Type: Article

References (69)

1. Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci 2000;23:1-11.
2. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-1038.
3. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
4. Jacob S, Praz F. DNA mismatch repair defects: Role in colorectal carcinogenesis. Biochimie 2002;84:27-47.
5. Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: Lessons from hereditary cancer syndromes. Cancer Biol Ther 2002;1:477-485.
6. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003;3:589-596.
7. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-3079.
8. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
9. Tomlinson IPM, Bodmer WF. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat Med 1999;5:11-12.
10. Vineis P. Cancer as an evolutionary process at the cell level: An epidemiological perspective. Carcinogenesis 2003;24:1-6.
11. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-341.
12. Li R, Sonik A, Stindl R, Rasnick D, Duesberg P. Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci USA 2000;97:3236-3241.
13. Wang T-L, Rago C, Silliman N, et al. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci USA 2002;99:3076-3080.
14. Vasquez KM, Wilson JH. Triplex-directed modification of genes and gene activity. Trends Biochem Sci 1998;23:4-9.
15. Giovannangeli C, Helene C. Triplex-forming molecules for modulation of DNA information processing. Curr Opin Mol Ther 2000;2:288-296.
16. Vasquez KM, Glazer PM. Triplex-forming oligonucleotides: Principles and applications. Q Rev Biophys 2002;35:89-107.
17. Vasquez KM, Wensel TG, Hogan ME, Wilson JH. High-efficiency triple-helix-mediated photo-cross-linking at a targeted site within a selectable mammalian gene. Biochemistry 1996;35:10712-10719.
18. Wang G, Levy DD, Seidman MM, Glazer PM. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol 1995;15:1759-1768.
19. Wang G, Seidman MM, Glazer PM. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 1996;271:802-805.
20. Vasquez KM, Christensen J, Li L, Finch RA, Glazer PM. Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions. Proc Natl Acad Sci USA 2002;99:5848-5853.
21. Vasquez KM, Narayanan L, Glazer PM. Specific mutations induced by triplex-forming oligonucleotides in mice. Science 2000;290:530-533.
22. Mahloogi H, Bassi DE, Klein-Szanto AJP. Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 2002;23:565-572.
23. Zenklusen JC, Oshimura M, Barrett JC, Conti CJ. Human chromosome 11 inhibits tumorigenicity of a murine squamous cell carcinoma cell line. Genes Chromosomes Cancer 1995;13:47-53.
24. Zenklusen JC, Oshimura M, Barrett JC, Conti CJ. Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. Oncogene 1994;9:2817-2828.
25. Bonfil RD, Momiki S, Conti CJ, Klein-Szanto AJP. Benzoyl peroxide enhances the invasive ability of a mouse epidermal carcinoma cell line. Int J Cancer 1989;44:165-169.
26. Klann RC, Fitzgerald DJ, Piccoli C, Slaga TJ, Yamasaki H. Gap-junctional intercellular communication in epidermal cell lines from selected stages of SENCAR mouse skin carcinogenesis. Cancer Res 1989;49:699-705.
27. Spiegelman VS, Budunova IV, Carbajal S, Slaga TJ. Resistance of transformed mouse keratinocytes to growth inhibition by glucocorticoids. Mol Carcinog 1997;20:99-107.
28. Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, Slaga TJ. In vivo behavior of murine epidermal cell lines derived from initiated and noninitiated skin. Cancer Res 1988;48:435-439.
29. La E, Muga SJ, Locniskar MF, Fischer SM. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis. Mol Carcinog 1999;24:276-286.
30. Beal PA, Dervan PB. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science 1991;251:1360-1363.
31. Cooney M, Czernuszewicz MG, Postel EH, Flint SJ, Hogan ME. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 1988;241:456-459.
32. Vasquez KM, Wensel TG, Hogan ME, Wilson JH. High-affinity triple helix formation by synthetic oligonucleotides at a site within a selectable mammalian gene. Biochemistry 1995;34:7243-7251.
33. Zendegui JG, Vasquez KM, Tinsley JH, Kessler DJ, Hogan ME. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res 1992;20:307-314.
34. Zernik-Kobak M, Pirsel M, Doniger J, DiPaolo JA, Levine AS, Dixon K. Polyomavirus-based shuttle vectors for studying mechanisms of mutagenesis in rodent cells. Mutat Res 1990;2421:57-65.
35. Seidman MM, Dixon K, Razzaque A, Zagurski RJ, Berman ML. A shuttle vector plasmid for studying carcinogen-induced point mutations in mammalian cells. Gene 1985;38:233-237.
36. Vasquez KM, Wang G, Havre PA, Glazer PM. Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res 1999;27:1176-1181.
37. Vasquez KM, Dagle JM, Weeks DL, Glazer PM. Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J Biol Chem 2001;276:38536-38541.
38. Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Genet 1996;30:603-636.
39. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112.
40. Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002;511:45-62.
41. Andrew SE, Xu XS, Baross-Francis A, et al. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. Carcinogenesis 2000;21:1291-1295.
42. Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2. Proc Natl Acad Sci USA 1997;94:3122-3127.
43. Richards B, Zhang H, Phear G, Meuth M. Conditional mutator phenotypes in hMSH2-deficient tumor cell lines. Science 1997;277:1523-1526.
44. Glaab WE, Tindall KR. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997;18:1-8.
45. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995;55:2304-2309.
46. Baross-Francis A, Andrew SE, Penney JE, Jirik FR. Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability. Proc Natl Acad Sci USA 1998;95:8739-8743.
47. Baross-Francis A, Milhausen MK, Andrew SE, Jevon G, Jirik FR. Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene. Carcinogenesis 2000;21:1259-1262.
48. Zhang S, Lloyd R, Bowden G, Glickman BW, de Boer J. Thymic lymphomas arising in Msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum. Mutat Res 2002;500:67-74.
49. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 2000;97:14295-14300.
50. Vineis P, Matullo G, Manuguerra M. An evolutionary paradigm for carcinogenesis? J Epidemiol Community Health 2003;57:89-95.
51. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability in cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 1998;95:13692-13697.
52. Matzke MA, Mette MF, Kanno T, Matzke AJM. Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet 2003;19:253-256.
53. Nowak MA, Komarova NL, Sengupta A, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci USA 2002;99:16226-16231.
54. Tomlinson IPM, Novelli MR, Bodmer WF. The mutation rate and cancer. Proc Natl Acad Sci USA 1996;93:14800-14803.
55. Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA, Bradley A. p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc Natl Acad Sci USA 1995;92:8517-8521.
56. Buettner VL, Hill KA, Nishino H, Schaid DJ, Frisk CS, Sommer SS. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53/Big Blue double transgenic mice. Oncogene 1996;13:2407-2413.
57. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003;100:776-781.
58. Haigis KM, Caya JG, Reichelderfer M, Dove WF. Intestinal adenomas can develop with a stable karyotype and stable microsatellites. Proc Natl Acad Sci USA 2002;99:8927-8931.
59. Young J, Leggett B, Gustafson C, et al. Genetic instability occurs in colorectal carcinomas but not it adenomas. Hum Mutat 1993;2:351-354.
60. Conti CJ, Aldaz CM, O'Connell J, Klein-Szanto AJP, Slaga TJ. Aneuploidy, an early event in mouse skin tumor development. Carcinogenesis 1986;7:1845-1848.
61. Aldaz CM, Conti CJ, Klein-Szanto AJP, Slaga TJ. Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: Relevance to malignancy. Proc Natl Acad Sci USA 1987;84:2029-2032.
62. Balmain A, Pragnell I. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 1983;303:72-74.
63. Bizub D, Wood A, Skalka A. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 1986;83:6048-6052.
64. Roop DR, Lowy DR, Tambourin PE, et al. An activated Harvey-ras oncogene produces benign tumors on mouse epidermal tissue. Nature 1986;323:822-824.
65. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
66. Bianchi AB, Aldaz CM, Conti CJ. Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors. Proc Natl Acad Sci USA 1990;87:6902-6906.
67. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994;22:3551-3555.
68. Ruggeri B, Caamano J, Goodrow T, et al. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression, Cancer Res 1991;51:6615-6621.
69. Ceccotti S, Ciotta C, Fronza G, Dogliotti E, Bignami M. Multiple mutations and frameshifts are the hallmark of defective hPMS2 in pZ189-transfected human tumor cells. Nucleic Acids Res 2000;28:2577-2584.